A phase 1b, multi-centre, parallel group, single blind study to evaluate the safety, tolerability and immunogenicity of a recombinant plague vaccine (rF1 and rV antigens) [Yersinia pestis vaccine] in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2008
At a glance
- Drugs Yersinia pestis vaccine (Primary)
- Indications Plague
- Focus Adverse reactions
- Sponsors PharmAthene
- 14 Sep 2008 Primary outcome identified as safety as reported by ClinicalTrials.gov
- 14 Sep 2008 Actual patient number (123) added as reported by ClinicalTrials.gov.
- 10 Sep 2008 PharmAthene reported as trial sponsor by ClinicalTrials.gov.